| Clinton E Preston, MD | |
|
1700 Geary St Se, Albany, OR 97322-6842 | |
| (541) 812-5500 | |
| (541) 812-5505 |
| Full Name | Clinton E Preston |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1700 Geary St Se, Albany, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467441048 | NPI | - | NPPES |
| 311187 | Other | WY | BLUE CROSS BLUE SHIELD |
| 114905900 | Medicaid | WY | |
| 0057811 | Medicaid | MT | |
| 080179382 | Other | WY | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 6238A (Wyoming) | Secondary |
| 207P00000X | Emergency Medicine | MD172857 (Oregon) | Primary |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.
Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.
Scientists from the National Institute of Allergy and Infectious Diseases, the National Institute of Dental and Craniofacial Research, and the National Heart, Lung and Blood Institute all parts of the National Institutes of Health, describe how combining engineered anthrax toxin proteins and existing chemotherapy drugs could potentially yield a therapy to reduce or eliminate cancerous tumors.
Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Clinton E Preston, MD 1700 Geary St Se, Albany, OR 97322-6842 Ph: (541) 812-5500 | Clinton E Preston, MD 1700 Geary St Se, Albany, OR 97322-6842 Ph: (541) 812-5500 |
News Archive
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.
Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.
Scientists from the National Institute of Allergy and Infectious Diseases, the National Institute of Dental and Craniofacial Research, and the National Heart, Lung and Blood Institute all parts of the National Institutes of Health, describe how combining engineered anthrax toxin proteins and existing chemotherapy drugs could potentially yield a therapy to reduce or eliminate cancerous tumors.
Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.
› Verified 5 days ago
Thomas Vanasche, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Geary St Se, Albany, OR 97322 Phone: 541-812-5500 | |
Evita Lopez, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1046 6th Ave Sw, Albany, OR 97321 Phone: 541-812-4000 | |
Anthony A Ferroggiaro, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1046 6th Ave Sw, Albany, OR 97321 Phone: 541-812-4000 | |
Megan Dell, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1046 6th Ave Sw, Albany, OR 97321 Phone: 541-812-4000 | |
Trevor Fisher, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1046 W 6th Avenue, Emergency Department, Albany, OR 97321 Phone: 503-926-2244 | |
Collin Andrew Wulff, DO (STUDENT) Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1046 6th Ave Sw, Albany, OR 97321 Phone: 541-812-4081 | |
Dr. Bruce Bohman, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 400 Hickory St Nw Ste 303, Albany, OR 97321 Phone: 541-812-5275 Fax: 541-812-5276 |